Indian big pharma R&D spend grows even as US growth slows

This has come in at a time when the revenue growth has slowed down

Indian pharma firms are gearing up to take on their global peers in terms of expenditure on research and development (R&D), which has shown a steady increase in the last five years. This has come in at a time when the revenue growth from both domestic business as well their US operations has slowed down. 

An analysis of the top seven pharma firms in the country including Cipla, Dr Reddy's Laboratories, Lupin, Aurobindo, Cadila Healthcare (Zydus), Sun Pharmaceuticals and Glenmark shows that their spend on R&D as a percentage of their operating income (OI) has increased from 5.8 per cent